Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic

• Verfasst von: Sebastian, Martin [VerfasserIn]
• Verfasst von: Eberhardt, Wilfried E. E. [VerfasserIn]
• Verfasst von: Heyde, Eyck von der [VerfasserIn]
• Verfasst von: Dörfel, Steffen [VerfasserIn]
• Verfasst von: Wiegand, Jörg [VerfasserIn]
• Verfasst von: Schiefer, Clemens [VerfasserIn]
• Verfasst von: Losem, Christoph [VerfasserIn]
• Verfasst von: Jänicke, Martina [VerfasserIn]
• Verfasst von: Fleitz, Annette [VerfasserIn]
• Verfasst von: Zacharias, Stefan [VerfasserIn]
• Verfasst von: Kaiser-Osterhues, Anja [VerfasserIn]
• Verfasst von: Hipper, Annette [VerfasserIn]
• Verfasst von: Dietel, Corinna [VerfasserIn]
• Verfasst von: Bleckmann, Annalen [VerfasserIn]
• Verfasst von: Benkelmann, Robin [VerfasserIn]
• Verfasst von: Boesche, Michael [VerfasserIn]
• Verfasst von: Grah, Christian [VerfasserIn]
• Verfasst von: Müller, Annette [VerfasserIn]
• Verfasst von: Griesinger, Frank [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Titel: Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic
• Titelzusatz: real-world data from the German prospective CRISP Registry (AIO-TRK-0315)
• Verf.angabe: Martin Sebastian, Wilfried E. E. Eberhardt, Eyck von der Heyde, Steffen Dörfel, Jörg Wiegand, Clemens Schiefer, Christoph Losem, Martina Jänicke, Annette Fleitz, Stefan Zacharias, Anja Kaiser-Osterhues, Annette Hipper, Corinna Dietel, Annalen Bleckmann, Robin Benkelmann, Michael Boesche, Christian Grah, Annette Müller, Frank Griesinger, Michael Thomas, for the CRISP Registry Group
• E-Jahr: 2024
• Jahr: 1 June 2024
• Umfang: 12 S.
• Illustrationen: Illustrationen
• Fussnoten: Zuerst veröffentlicht: 08. Februar 2024 ; Gesehen am 26.06.2024
• Titel Quelle: Enthalten in: International journal of cancer
• Ort Quelle: Bognor Regis : Wiley-Liss, 1966
• Jahr Quelle: 2024
• Band/Heft Quelle: 154(2024), 11 vom: Juni, Seite 1967-1978
• ISSN Quelle: 1097-0215
• DOI: doi:10.1002/ijc.34868
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cohort studies
• Sach-SW: COVID-19
• Sach-SW: non-small cell lung cancer
• Sach-SW: patient-reported outcomes
• Sach-SW: real world
• K10plus-PPN: 1892261480

Abstract

Patients with lung cancer under treatment have been associated with a high risk of COVID-19 infection and potentially worse outcome, but real-world data on patient-reported outcomes (PROs) are rare. We assess patients' characteristics and PROs before and during the COVID-19 pandemic in an advanced non-small cell lung cancer (NSCLC) cohort in Germany. Patients with locally advanced or metastatic NSCLC from the prospective, multicentre, observational CRISP Registry (NCT02622581) were categorised as pre-pandemic (March 2019 to Feb 2020, n = 1621) and pandemic (March 2020 to Feb 2021, n = 1317). From baseline to month 15, patients' health-related quality of life (HRQoL) was assessed by FACT-L, anxiety and depression by PHQ-4. Association of pandemic status with time to deterioration (TTD) in QoL scales adjusted for potential covariates was estimated using Cox modelling. PROs were documented for 1166 patients (72%) in the pre-pandemic, 979 (74%) in the pandemic group. Almost 60% of patients were male, median age was 66 years, comorbidities occurred in 85%. Regarding HRQoL, mean-change-from-baseline plots hardly differed between both samples. Approximately 15%-21% of patients reported anxiety, about 19%-27% signs of depression. For the pandemic group, TTD was slightly, but statistically significantly, worse for the physical well-being-FACT-G subscale (HR 1.15 [95%CI 1.02-1.30]) and the anxiety-GAD-2 subscale (HR 1.14 [95%CI 1.01-1.29]). These prospectively collected real-world data provide valuable insights into PROs before and during the COVID-19 pandemic in advanced NSCLC. For the patients, the pandemic seemed to be less of a burden than the disease itself, as there was a considerable proportion of patients with anxiety and depression in both groups.